Last reviewed 2026-04-23 · How we verify

G17DT-Irinotecan

Cancer Advances Inc. · Phase 2 active Biologic

G17DT-Irinotecan is a Topoisomerase I inhibitor Biologic drug developed by Cancer Advances Inc.. It is currently in Phase 2 development for Metastatic colorectal cancer.

G17DT-Irinotecan is a topoisomerase I inhibitor, which works by blocking the enzyme topoisomerase I and preventing DNA replication in cancer cells.

G17DT-Irinotecan is a topoisomerase I inhibitor, which works by blocking the enzyme topoisomerase I and preventing DNA replication in cancer cells. Used for Metastatic colorectal cancer.

At a glance

Generic name	G17DT-Irinotecan
Sponsor	Cancer Advances Inc.
Drug class	Topoisomerase I inhibitor
Target	Topoisomerase I
Modality	Biologic
Therapeutic area	Oncology
Phase	Phase 2

Mechanism of action

This mechanism of action is similar to that of irinotecan, a well-known chemotherapeutic agent. By inhibiting topoisomerase I, G17DT-Irinotecan prevents cancer cells from replicating and ultimately leads to cell death.

Approved indications

Metastatic colorectal cancer

Common side effects

Diarrhea
Fatigue
Nausea

Key clinical trials

Phase II Study to Evaluate G17DT in Combination With Irinotecan in Patients With Colorectal Carcinoma (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

G17DT-Irinotecan CI brief — competitive landscape report
G17DT-Irinotecan updates RSS · CI watch RSS
Cancer Advances Inc. portfolio CI

Frequently asked questions about G17DT-Irinotecan

What is G17DT-Irinotecan?

G17DT-Irinotecan is a Topoisomerase I inhibitor drug developed by Cancer Advances Inc., indicated for Metastatic colorectal cancer.

How does G17DT-Irinotecan work?

G17DT-Irinotecan is a topoisomerase I inhibitor, which works by blocking the enzyme topoisomerase I and preventing DNA replication in cancer cells.

What is G17DT-Irinotecan used for?

G17DT-Irinotecan is indicated for Metastatic colorectal cancer.

Who makes G17DT-Irinotecan?

G17DT-Irinotecan is developed by Cancer Advances Inc. (see full Cancer Advances Inc. pipeline at /company/cancer-advances-inc).

What drug class is G17DT-Irinotecan in?

G17DT-Irinotecan belongs to the Topoisomerase I inhibitor class. See all Topoisomerase I inhibitor drugs at /class/topoisomerase-i-inhibitor.

What development phase is G17DT-Irinotecan in?

G17DT-Irinotecan is in Phase 2.

What are the side effects of G17DT-Irinotecan?

Common side effects of G17DT-Irinotecan include Diarrhea, Fatigue, Nausea.

What does G17DT-Irinotecan target?

G17DT-Irinotecan targets Topoisomerase I and is a Topoisomerase I inhibitor.

Drug class: All Topoisomerase I inhibitor drugs
Target: All drugs targeting Topoisomerase I
Manufacturer: Cancer Advances Inc. — full pipeline
Therapeutic area: All drugs in Oncology
Indication: Drugs for Metastatic colorectal cancer
Compare: G17DT-Irinotecan vs similar drugs
Pricing: G17DT-Irinotecan cost, discount & access